Addex Therapeutics, a Swiss pioneer in allosteric modulation-based oral small molecule drug discovery and development, has appointed Graham Dixon to the newly created position of chief scientific officer and head of research.
Dixon reports to Bharat Chowrira, ceo, and will be responsible for leading all aspects of research and non-clinical development activities at the firm.
He joins Addex with more than 20 years of experience in pharmaceutical research, most recently as chief scientific officer at Galapagos. In this role, Dixon was responsible for all research and early development within the company in multiple therapeutic areas as well as the management of more than 260 scientific personnel across three sites in the Netherlands, Belgium and France.
Prior to Galapagos, he was chief scientific officer at Entomed, a developer of natural anticancer and anti-infective agents. Dixon joined Entomed from a similar role at antifungal therapeutic company, F2G. Before this, he held several roles at AstraZeneca. He started his career as head of Biochemistry at Dowelanco (UK).
